2. Inhibitory Antibodies

Inhibitory Antibodies

100+ hot targets In vivo grade antibodies Specific validation
FAQ

MedChemExpress (MCE) Inhibitory Antibodies are research-grade biosimilar antibodies that have the same bioactive component as the original therapeutic antibodies. Biosimilar makes it possible to study the biological effects of a drug.

These antibodies bind specifically to target cells or proteins, either stimulating the immune system to attack the malignant tumor cells or preventing tumor growth by blocking specific cell receptors. Target proteins include CD20, HER2, EGFR, VEGFR, TNF-alpha, etc. MCE Inhibitory Antibodies have been extensively used in the most popular research fields, such as cancer, immunology and infection.

Inhibitory Antibodies

PDF 0.41 MB

Inhibitory Antibodies (1842):

Cat. No. Product Name Purity
  • HY-P9907
    Trastuzumab
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
  • HY-P9905
    Cetuximab 99.70%
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-P9906
    Bevacizumab ≥99.0%
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-108841
    Raleukin ≥99.4%
    Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects.
  • HY-P9904
    Atezolizumab ≥98.0%
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9902
    Pembrolizumab ≥98.0%
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P99001
    Human IgG1 kappa, Isotype Control
    Human IgG1 kappa, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1 kappa antibody.
  • HY-P9926
    Dupilumab ≥99.2%
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
  • HY-P9970
    Infliximab
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
  • HY-P99144
    Anti-Mouse PD-1 Antibody (RMP1-14)
    Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG2a antibody inhibitor.
  • HY-P9913
    Rituximab 99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
  • HY-P9917
    Tocilizumab 99.67%
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
  • HY-P9903
    Nivolumab ≥99.0%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P99145
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) 99.60%
    Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1.html" class="link-product" target="_blank">PD-L1 IgG2b antibody inhibitor derived from host rat.
  • HY-P99045
    Sacituzumab
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer.
  • HY-P9908
    Adalimumab ≥98.0%
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P99355
    Bimagrumab ≥99.0%
    Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
  • HY-108847
    Etanercept ≥98.0%
    Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
  • HY-P99003
    Human IgG4 (S228P) kappa, Isotype Control
    Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.
  • HY-P9915
    Daratumumab 99.00%
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.